Omeros (OMER) to Offer $40M in Common Stock

August 10, 2016 4:03 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Omeros Corporation (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co., as the sole underwriter, in a registered underwritten public offering.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including funding research and development expenses for its clinical OMS721 program and clinical trials, pre-clinical studies, manufacturing development and other costs associated with advancing its product candidates toward Biologic License Application and New Drug Application submissions, and supporting the continued commercialization of OMIDRIA. The net offering proceeds may also be used for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Equity Offerings

Related Entities

Cantor Fitzgerald, S3

Add Your Comment